Gastroenterology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global pharma market insights for gastroenterology: track drug development, regulatory approvals, and M&A for IBD, liver disease, and GI oncology.
Showing 1–6 of 6 articles
Quick answer
NovaPharmaNews Gastroenterology hub for FDA covers 6 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026
MRM Health's MH002 Receives FDA Fast Track Designation for Ulcerative Colitis Treatment
RedHill's RHB-204 Shows Comparable Efficacy to RHB-104 in Crohn's Disease MAP Treatment Development
ASCO 2026: Key Oncology Data Readouts to Watch
SAHPRA Accelerated Review Program: One Year Assessment & Oncology Approval Trends
Dr. Falk Pharma and Renexxion Announce Naronapride Phase 2b Gastroparesis Results at DDW 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.